Life Science News

- Johnson & Johnson (NYSE: JNJ) (the Company) today announced the appointment of several senior leaders to the Company's Executive Committee. Separately, the Company announced that Mr. Michael Sneed Executive Vice President, Global Corporate Affairs and Chief Communication Officer, will be retiring on April 1, 2022 .

As previously announced, Mr. Alex Gorsky will serve as Executive Chairman of Johnson & Johnson and transition the Chief Executive Officer role to Mr. Joaquin Duato , currently Vice Chairman of the Company's Executive Committee, effective January 3, 2022 . From that time, all members of the Executive Committee will report to Mr. Duato.

The new Executive Committee appointments are as follows:

  • Ms. Vanessa Broadhurst , Company Group Chairman, Global Commercial Strategy Organization, has been appointed Executive Vice President, Global Corporate Affairs.
  • Dr. Bill Hait , Global Head of Johnson & Johnson External Innovation, has been appointed Executive Vice President, Chief External Innovation, Medical Safety and Global Public Health Officer.
  • Dr. Mathai Mammen , Global Head of R&D at the Janssen Pharmaceutical Companies of Johnson & Johnson, has been appointed Executive Vice President, Pharmaceuticals, R&D.
  • Mr. James (Jim) Swanson , Chief Information Officer, has been appointed Executive Vice President, Chief Information Officer.

Mr. Duato said, "I am thrilled to appoint this group of dynamic and experienced leaders to Johnson & Johnson's Executive Committee. Each represents a high level of dedication to our mission, as well as proven track records of strategic thinking, strong execution, and Credo-based leadership. As a whole, they are representative of the deep bench of talent we see at every level of our organization, as well as the tremendous opportunity ahead for Johnson & Johnson as we enter a new and exciting chapter."

Mr. Duato continued, "At the same time, I want to extend my warmest wishes and congratulations to my friend and colleague Michael Sneed on his retirement. Since joining the Johnson & Johnson team more than 38 years ago, Michael has been the Company's tireless champion in amplifying our vision, values, and success. On behalf of the entire Board and Executive Committee, I thank Michael for his extraordinary leadership and work in cultivating a unique company culture."

Dr. Peter Fasolo , Executive Vice President, Chief Human Resources Officer; Ms. Ashley McEvoy , Executive Vice President, Worldwide Chairman, Med Tech; Mr. Thibaut Mongon , Executive Vice President, Worldwide Chairman, Consumer Health; Ms. Jennifer Taubert , Executive Vice President, Worldwide Chairman, Pharmaceuticals; Mr. Michael Ullmann , Executive Vice President, General Counsel; Ms. Kathy Wengel , Executive Vice President, Chief Global Supply Chain Officer; and Mr. Joseph Wolk , Executive Vice President, Chief Financial Officer will remain on the Executive Committee.

As previously announced, Dr. Paul Stoffels , Vice Chairman of the Executive Committee and Chief Scientific Officer, will retire from the Company effective December 31, 2021 .

About Johnson & Johnson
At Johnson & Johnson, we believe good health is the foundation of vibrant lives, thriving communities and forward progress. That's why for more than 130 years, we have aimed to keep people well at every age and every stage of life. Today, as the world's largest and most broadly-based health care company, we are committed to using our reach and size for good. We strive to improve access and affordability, create healthier communities, and put a healthy mind, body and environment within reach of everyone, everywhere. We are blending our heart, science and ingenuity to profoundly change the trajectory of health for humanity.

Note to Investors Concerning Forward-Looking Statements
This press release contains "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995. The reader is cautioned not to rely on these forward-looking statements. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or known or unknown risks or uncertainties materialize, actual results could vary materially from the expectations and projections of Johnson & Johnson. A list and descriptions of risks, uncertainties and other factors can be found in Johnson & Johnson's Annual Report on Form 10-K for the fiscal year ended January 3, 2021 , including in the sections captioned "Cautionary Note Regarding Forward-Looking Statements" and "Item 1A. Risk Factors," and in the Company's subsequent Quarterly Reports on Form 10-Q and other filings with the Securities and Exchange Commission. Copies of these filings are available online at www.sec.gov , www.jnj.com or on request from Johnson & Johnson. Any forward-looking statement made in this release speaks only as of the date of this release. Johnson & Johnson does not undertake to update any forward-looking statement as a result of new information or future events or developments .

View original content to download multimedia: https://www.prnewswire.com/news-releases/johnson--johnson-appoints-senior-leaders-to-executive-committee-301440952.html

SOURCE Johnson & Johnson

News Provided by PR Newswire via QuoteMedia

Knight Therapeutics Enters into Exclusive License and Supply Agreements with Rigel Pharmaceuticals to Commercialize Fostamatinib in Latin America

Knight Therapeutics Inc. (TSX: GUD), a pan-American (ex-USA) specialty pharmaceutical company, today announced that it has entered into exclusive license and supply agreements with Rigel Pharmaceuticals granting Knight the rights to commercialize fostamatinib, an oral spleen tyrosine kinase (SYK) inhibitor, in Latin America.

Fostamatinib is commercially available in the United States under the brand name TAVALISSE ® (fostamatinib disodium hexahydrate) and in Europe under the brand name TAVLESSE ® for the treatment of chronic immune thrombocytopenia (ITP). Fostamatinib is also currently being studied in a Phase 3 clinical trial for the treatment of warm autoimmune hemolytic anemia (wAIHA) 1 and in two Phase 3 clinical trials for the treatment of hospitalized patients with COVID-19. 2,3

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less
ALR Technologies

ALR Technologies Announces Reincorporation Merger

ALR Technologies Inc. ("ALRT USA") (OTCQB: ALRT), the diabetes management company, today announces that further to its release on June 1, 2021, ALRT USA has entered into an Agreement and Plan of Merger and Reorganization (the "Reincorporation Merger Agreement") with ALR Technologies SG Pte. Ltd., a Singapore company limited by shares ("ALRT Singapore"), and its wholly-owned subsidiary, ALRT Delaware, Inc., a Delaware corporation ("ALRT Delaware"), relating to a proposed merger transaction (the "Reincorporation Merger") for the purpose of changing the jurisdiction of incorporation of ALRT USA from Nevada to Singapore.

The Reincorporation Merger will consist of a one-for-one share exchange, where at closing of the transaction, ALRT Delaware will merge with and into ALRT USA, and ALRT USA will be the surviving entity and a wholly-owned subsidiary of ALRT Singapore. ALR Delaware will then cease to exist. At closing, the stockholders of ALRT USA will exchange their shares of common stock, and any options or warrants to purchase shares of common stock which they might hold, on a one-for-one basis, for ordinary shares ("ALRT Singapore Ordinary Shares") and options or warrants to subscribe for ALRT Singapore Ordinary Shares, as applicable. The shareholders of ALRT USA prior to the transaction will have the same number of shares and same proportionate ownership of ALRT Singapore as held in ALRT USA. The parties to the Reincorporation Merger expect that the ALRT Singapore Ordinary Shares will trade on the OTCQB subsequent to the close of the transaction.

Keep reading...Show less

Medtronic to announce financial results for its fourth quarter and full fiscal year 2022

Medtronic plc (NYSE:MDT), a global leader in healthcare technology, today announced that it will report financial results for its fourth quarter and full fiscal year 2022 on Thursday, May 26, 2022 . A news release will be issued at approximately 5:45 a.m. Central Daylight Time (CDT) and will be available at https:news.medtronic.com . The news release will include summary financial information for the company's fourth quarter and full fiscal year 2022, which ended on Friday, April 29, 2022 .

Medtronic will host a video webcast at 7:00 a.m. CDT on Thursday , May 26, 2022, to discuss financial results for its fourth quarter and full fiscal year 2022. The webcast can be accessed at https://investorrelations.medtronic.com .

News Provided by Canada Newswire via QuoteMedia

Keep reading...Show less

New Late-Breaking Data Highlight Abbott Structural Heart Transcatheter Valve Therapies

  • Data presented at EuroPCR 2022 reinforce the impact of Abbott's minimally invasive heart devices on patient outcomes and quality of life
  • Findings demonstrate TriClip™ transcatheter edge-to-edge (TEER) repair is effective at reducing tricuspid regurgitation across a broad range of anatomies
  • One-year outcomes for Navitor™ transcatheter aortic valve implantation (TAVI) system show the safety and effectiveness of this therapy and durable performance of the sealing cuff in minimizing paravalvular leak for patients with severe aortic stenosis

Abbott (NYSE: ABT) today announced two late-breaking data presentations highlighting both TriClip™, a first-of-its kind minimally invasive tricuspid heart valve repair device, and Navitor™, the company's latest-generation transcatheter aortic valve implantation (TAVI) system. The company also showcased new data for MitraClip™ and Amplatzer™ Amulet™, two key components of the company's industry-leading structural heart portfolio.

All data were presented at EuroPCR, the annual meeting of the European Association of Percutaneous Cardiovascular Interventions, held in Paris from May 17-20, 2022 .

News Provided by PR Newswire via QuoteMedia

Keep reading...Show less

Thermo Fisher Scientific Declares Quarterly Dividend

Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, today announced that on May 18, 2022, its Board of Directors authorized a quarterly cash dividend of $0.30 per common share, payable on July 15, 2022, to shareholders of record as of June 15, 2022.

About Thermo Fisher Scientific

News Provided by Business Wire via QuoteMedia

Keep reading...Show less
Premier Health Reports FY2022 Second Quarter Results

Premier Health Reports FY2022 Second Quarter Results

Premier Health of America Inc. (TSXV: PHA ) (the " Corporation "), a leading Canadian Healthtech company, announces it has filed its Condensed Interim Consolidated Financial Statements and Management Discussion and Analysis for its second quarter ended March 31, 2022.

Summary

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less

Latest Press Releases

Related News

×